Europe Antiviral Drugs Market size exceeded USD 8.5 million in 2020 and is projected to register a growth of over -1.9% from 2021 to 2027.
Anti-viral drugs are the medicines that can treat symptoms related to viral infections and diseases. These drugs are prescription medicine such as pills, liquid, an inhaled powder, and intravenous solution.
Get more details on this report - Request Free Sample PDF
Incidence of COVID-19 has significantly increased the usage of anti-viral drugs. Growing number of drug approvals coupled with increasing drug production for COVID-19 treatment are the factors contributing to the market growth. The use of anti-viral drugs significantly decreases the viral load and infection. Anti-viral drugs, in the combination with isolation, contact tracing, and quarantine, resulted in significant decrease in the final size of peak incidence of infection.
Increasing marketing authorisation for COVID-19 prescription drugs will augment demand for the drugs in near future. For instance, in September 2020, Russia authorised the first COVID-19 drug, Coronavir for sale in pharmacies. Russia has approved the usage of drugs for patients with mild to moderate infections. For instance, in July 2020, European Commission signed a contract with Gilead to secure treatment of doses of Remdesivir.
The reverse transcriptase inhibitors segment held more than 40% market share in 2020 due to wide usage of reverse transcriptase inhibitors in various applications. In addition, increasing use of reverse transcriptase inhibitors in HIV and increasing FDA approval of these drugs are the factors increasing the drug usage.
The HIV AIDS segment dominated over 50% market share in 2020. Increasing cases of HIV AIDS coupled with growing use of anti-viral drugs in HIV treatment are the factors are contributing to the market size. According to the National AIDS Trust, in 2019, there were 105,200 people living with HIV in the UK.
The branded drugs observed high demand in 2020 owing to high cost of drugs. Branded drugs have original drug class that are developed and manufactured by original pharmaceutical company. Increasing research and development expenditure and rising demand for branded drugs for various infectious diseases due to greater specificity and efficacy are the factors stimulating the market revenue.
The geriatric segment accounted for high market revenue share in 2020 on account of rising incidence of various chronic and infectious disease. Growing baby boomer population coupled with high cost of treatment are the factors contributing to the growth of the market. According to the Eurostat, there were more than 20% of the EU-27 population, aged 65 years and over.
Germany antiviral drugs market size was more than USD 1 billion in 2020. Increasing use of anti-viral medicines for treatment of various infectious disease such as coronavirus and Hepatitis will boost the market demand. Moreover, rising geriatric population is prone to various chronic and infectious disease, thereby increasing the demand for anti-viral therapeutics. According to the American Association of Retired Persons stats, Germany is one of only five “Super-aged” societies in the world. The population of Germany aged 65 years and over is estimated to grow by 41% to 24 million by 2050.
Some of the established industry players are Gilead Science, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, AstraZeneca, and Abbvie. Market players are expediting research and development activities and speedy approval of anti-viral drugs in the region. For instance, in March 2020, scientists at German Primate Center- Leibniz Institute for Primary Research identified potential drug for COVID-19.